# US 2016/0354499 A1 · Radio-imaging and radio-therapy of cancer using antibodies to haah

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354499 A1
- Document ID: US20160354499A1
- Status: Published application
- Kind: A1
- Application number: 15/174,239
- Filed: 2016-06-06
- Published: 2016-12-08
- Earliest claimed: 2015-06-05
- Assignees: Panacea Pharmaceuticals, Inc.
- Applicants: Panacea Pharmaceuticals Inc.
- Inventors: Hossein A. GHANBARI; Steven Andrew FULLER
- Web page: https://patentgrep.com/patent/US20160354499A1

## CPC

- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 51/1075: {the antibody being against an enzyme}
- A61K 51/1093: {conjugates with carriers being antibodies}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61P 35/00: Antineoplastic agents
- C07K 16/30: from tumour cells
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-HAAH antibodies for tumor imaging and immunotherapy are provided.

## Claims

### Claim 1

A method for killing cancer cells, comprising the steps of:
conjugating a radioisotope to an antibody which binds to human aspartyl (asparaginyl) β-hydroxylase (HAAH) to form a radiolabeled antibody and contacting cancer cells with the radiolabeled antibody which binds to HAAH, thereby killing the cancer cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein said radioisotope is selected from the group consisting of 213Bi, 90Y and 111In.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer cells are leukemia cells.

### Claim 4 (depends on 3)

The method of claim 3, wherein the radioisotope is 213Bi.

### Claim 5 (depends on 4)

The method of claim 4, wherein the antibody which binds to HAAH is PAN-622.

### Claim 6

A method for treating cancerous tissue in a mammal, comprising the steps of:
conjugating a radioisotope to an antibody which binds to human aspartyl (asparaginyl) β-hydroxylase (HAAH) to form a radiolabeled antibody and contacting cancerous tissue of said mammal with the radiolabeled antibody which binds to HAAH.

### Claim 7 (depends on 6)

The method of claim 6, wherein said radioisotope is 213Bi.

### Claim 8 (depends on 6)

The method of claim 6, wherein said radioisotope is 111In.

### Claim 9 (depends on 6)

The method of claim 6, wherein said radioisotope is 90Y.

### Claim 10 (depends on 8)

The method of claim 8, wherein the antibody which binds to HAAH is PAN-622.

### Claim 11 (depends on 9)

The method of claim 9, wherein the antibody which binds to HAAH is PAN-622.

### Claim 12

A radioimmunoconjugate comprising a chelating agent, a radioisotope, and a fully human anti-HAAH antibody.

### Claim 13 (depends on 12)

The radioimmunoconjugate of claim 12, wherein the radioisotope is 213Bi.

### Claim 14 (depends on 12)

The radioimmunoconjugate of claim 12, wherein the radioisotope is

### Claim 15 (depends on 12)

The method of claim 12, wherein said radioisotope is 90Y.

### Claim 16 (depends on 12)

The radioimmunoconjugate of claim 12, wherein the fully human anti-HAAH antibody is PAN-622.